Elomotecan

Drug Profile

Elomotecan

Alternative Names: BN 80927; R 1559

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ipsen
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Cancer

Most Recent Events

  • 08 Jun 2010 Adverse events, pharmacokinetics and efficacy data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
  • 22 Mar 2007 Elomotecan is still in phase I trials for Solid tumours in European Union
  • 22 Apr 2004 No development reported - Preclinical for Cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top